ERBB2 and neoplasm: Beyond IHC and FISH, when HER2 amplification was determined by next-generation sequencing (NGS) in tumor samples or in plasma, analyzing cell-free circulating tumor DNA, response to antiHER2 agents directly correlated with level of expression observed in plasma samples.